PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Negative net income growth while CRVO stands at 22.57%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
77.92%
D&A growth well above CRVO's 13.96%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Deferred tax of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
Less SBC growth vs. CRVO's 454.74%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
56.13%
Less working capital growth vs. CRVO's 114.62%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
AP growth well above CRVO's 111.52%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-0.47%
Both reduce yoy usage, with CRVO at -55.39%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
85.22%
Some yoy increase while CRVO is negative at -100.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-64.88%
Negative yoy CFO while CRVO is 57.79%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
82.30%
CapEx growth of 82.30% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
We expand invests by 82.30% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-39.13%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.